Argen-X Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/22/2026)
| Balance Sheet | Total Assets | 8,683,730,000.00 | ROE | 84.34 % |
| Balance Sheet | Total Equity | 7,323,960,000.00 | ROA | 15.49 % |
| Cashflow | Capital Expenditures | -64,163,400.00 | P/FCF | 60.21 |
| Cashflow | Free Cash Flow | 818,265,856.00 | – | – |
| Cashflow | Operating Cash Flow | 882,429,000.00 | P/CF | 55.84 |
| Income | Earnings per Share (diluted) | 20.37 | Div. Yield | – |
| Income | Net Income | 1,344,710,000.00 | P/E | 36.63 |
| Income | Shares Outstanding | 66,029,200.00 | P/B | 6.73 |
| Income | Total Revenue | 4,320,560,000.00 | P/S | 11.40 |
Ratios calculated on: 10/14/2026
Company Description
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.argenx.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more